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Abstract 
 The aim of the present study was to analyze the in vivo hypoglycaemic effects of both 
decoction of Smallanthus macroscyphus leaves and pure crystalline polymatin A isolated 
from its leaves. Phytochemical analysis of the leaf decoction showed that its major 
constituents were caffeic, chlorogenic and three dicaffeoilquinic acids, together with the 
sesquiterpene lactone  polymatin A. Oral glucose tolerance test in normal rats was 
performed to evaluate the hypoglycemic activity and to choose the minimum effective dose of 
the decoction and polymatin A. They have effective hypoglycemic activity at the minimum 
dose of 140 mg dry extract and 14 mg crystalline powder/kg body weight, respectively, and 
were selected for the following experiments. Oral administration of a single-dose of decoction 
produced a moderate lowering effect in fasting glycemia of normal rats, whereas polymatin A 
had no significant effect. We also assessed the effect of a single-dose on post-prandial blood 
glucose, resulting in an inhibition of the hyperglycemic peak after sucrose overload. Daily 
administration of decoction or polymatin A for 4 weeks produced an effective glycemic 
control in diabetic animals, with a decrease in urinary glucose excretion and a significant 
reduction in the HbA1c levels. Although there were no significant increases in plasma insulin 
levels, both treatments improved the fasting blood glucose/insulin ratio. In vivo acute toxicity 
studies were performed in adult Wistar rats. There were no deaths or signs of toxicity 
observed after oral administration of decoction or polymatin A at any dose level up to the 
highest dose tested (14.0 g /kg and 2.8 g /kg, respectively).  
 The results presented here strongly support the notion that S. macroscyphus 
represents a new source of antidiabetic compounds that could help to manage diabetes 
more efficiently and safely. 
  
1. Introduction 
 Smallanthus macroscyphus (Baker ex Martius) A. Grau (Heliantheae, Asteraceae), a 
perennial herb commonly known as “wild yacon”, is indigenous to South America from 
southern Bolivia to northwestern Argentina [1]. This specie is an invader of abandoned sugar 
cane fields as well as of the free space between the plots of land. It belongs to the 
Smallanthus genus, whosemost relevant member is the species S. sonchifolius (Poepp. and 
Endl.) H. Robinson or “yacon” due to it wide range of medicinal and nutritional properties 
[1,2,3,4,5,6,7]. S. sonchifolius is probably an allotetraploid species, with “wild yacon” (S. 
macroscyphus) as one of the putative parents [1]. Yacon is a pre-columbian culture whose 
consumption has gained in importance during the last decades by consumption from its roots 
as a functional food or nutraceutical and its leaves as a hypoglycemic infusion. This allows 
us to hypothesize that the leaves of S. macroscyphus, species belonging to the same genus 
could also contain active principles with hypoglycemic activity.  
 Unlike yacon, there is no available oral or written information concerning the use of 
the wild species of the genus Smallanthus in folk medicine and even less of their biological 
activities. There is only one study carried out in farming communities in the Upper Bermejo 
Basin, province of Salta, Argentina, documenting the use of S. macroscyphus as a plant in 
the manufacture of “yista”, which is used during the insalivation of “coca” (Erythroxylum coca 
Lam.var. coca) leaves [8]. Considering geographical distribution, growth habitat and 
morphology of the aerial parts, S.macroscyphus appears as specie closely related to S. 
sonchifolius and perhaps with a similar chemical composition and biological activities [1]. 
 Diabetes mellitus is a metabolic disorder which characterizes by hyperglycemia 
resulting from defects in insulin secretion, insulin action or both. It has been demonstrated 
that tight control of blood glucose is effective in reducing clinical complications and improves 
the quality of life of diabetic patients [9,10]. However, treatments with modern drugs are also 
  
associated with side effects and fail to significantly alter the course of diabetic complications, 
suggesting that alternative treatment strategies are required. In this regard, the World Health 
Organization has recommended the evaluation of medicinal plants or their extracts that can 
help to reverse disease progression and plans to incorporate "traditional medicine" into the 
next revision of its International Classification of Diseases [11]. Numerous studies conducted 
over the last few years have been focused on the discovery, development and evaluation of 
plants and their byproducts for therapeutic management of diabetes because of their ready 
availability, affordability and anti-diabetic effectiveness [12].  
 In a preliminary experimental test to evaluate new medicinal plants with anti-diabetic 
activity, we demonstrated that the aqueous extracts of dried S. macroscyphus leaves exert a 
hypoglycemiant effect on rats [13], greater than the one demonstrated by yacon leaves [5]. 
These findings represented a first step toward the assessment of S. macroscyphus leaves as 
a product with beneficial action on diabetes and have led us to continue the study of the 
medicinal properties of this species. 
 About 1000 plants worldwide are used ethnopharmacologically to treat symptoms of 
diabetes mellitus or experimentally to confirm their efficacy, mechanism of action and safety, 
the Fabaceae and Asteraceae families being most frequently cited. At the present, there are 
more than 200 pure compounds from plant sources reported to show blood glucose lowering 
activity [14,15] and the wide variety of classes of chemical compounds indicates that 
different mechanisms must be involved in this effect.  
 Naturally occurring chemicals produced by plants are stored in various organs 
including leaves, stems and roots. In particular, the glandular trichomes on the leaf surfaces 
are specialized secretors structures that might be the sites of production or accumulation of 
various bioactive secondary metabolites [16]. These chemical compounds may have diverse 
functions, including the plant defense [17], and could be of interest as pesticides or 
  
pharmaceutical products.  Melampolide-type sesquiterpene lactones (STLs) are 
characteristic secondary metabolites of the genus Smallanthus produced in glandular 
trichomes of the foliar surface [18]. Polymatin A is a STLs isolated as a gum from 
Smallanthus siegesbeckia [19]  and Smallanthus maculatus var. maculatus [20]. So far, 
nineteen melampolide-type STLs have been isolated and identified in S. sonchifolius leaves 
[21], enhydrin being the more abundant. With regard to the chemical constituents of S. 
macroscyphus leaves, de Pedro et al. [22] have determined the presence of small amounts 
of a mixture of STLs among which polymatin A was identified by 1H NMR spectrometry and 
MS analysis as the predominant STL in this species. Fig 1 shows the chemical structure of 
the polymatin A. 
 In a previous work we isolated enhydrin, the main lactone from leaf extracts of S. 
sonchifolius, and we found it to be an active compound useful in the decrease post-prandial 
blood glucose levels and in the treatment of diabetic Wistar rats [5]. These results strongly 
suggest that the STLs would be very important active anti-diabetic principles from the leaves 
of the Smallanthus genus. Since S. macroscyphus is a slight departure from the previously 
studied specie S. sonchifolius, we think that polimatin A may represent another interesting 
chemical entity with anti-diabetic properties. 
 Despite their natural origin, the use of medicinal plants extracts containing a very 
complex mix of chemical compounds may cause adverse effects and medicine interactions 
[23]. In addition, STLs also may cause acute or chronic toxicity [24]. In a recent study we 
provided evidence that the use of a 10% decoction of yacon leaves or pure crystalline 
enhydrin isolated from yacon leaves was safe in rats at doses in which the hypoglycemic 
effect was demonstrated [25]. Further studies are required to assess the efficacy/safety ratio 
of S. macroscyphus leaves as a product with beneficial action on diabetes. 
  
 In view of the close relationship between yacon and the wild species S. 
macroscyphus, it is important to characterize the biological activity as well as the potential 
toxic effects of the latter species. Therefore, the aim of the present study was to analyze the 
hypoglycemic effects in normal and diabetic rats of both the aqueous extract of Smallanthus 
macroscyphus leaves and the pure crystalline polymatin A isolated from them. This study 
represents a first step toward the assessment of new medicinal plants and new chemical 
entities isolated from them, which could help to manage diabetes with greater efficiency and 
safety. 
  
2. Materials and methods 
2.1. Plant material 
 Leaves of Smallanthus macroscyphus (Baker ex Martius) Grau were collected in 
February 2010 from an experimental field (Regional Ecology Institute (IER), National 
University of Tucumán, located at Horco Molle, Yerba Buena, province of Tucumán, 
Argentina, 26º47’ S, 65º19’ W, 547 m.a.s.l. The plant material at the experimental field was 
grown from rhizomes possessing young buds of wild plants collected at Rearte, Trancas 
Department, province of Tucumán, Argentina, 26º20’ S, 65º32’ W, 1450 m.a.s.l. A voucher 
specimen (LIL607375) is on deposit in the herbarium of “Fundación Miguel Lillo”. 
 
2.2. Preparation of the aqueous extract 
Fresh plant material was carefully dried under air flow in an oven between 40° and 
45ºC and ground to a powder. Aqueous extract of the leaves (decoction) was prepared 
boiling 10 g dried powder in 100 mL distilled water under reflux for 10 min. The decoction 
obtained (10 %) was filtered, frozen at -20 ºC and then lyophilized. The yield in dry residue 
was 1.8 g (18%, w/w), which was stored at -20 ºC until used. The appropriate amount of dry 
residue was dissolved in distilled water immediately before each experiment. In the present 
work, a 10% decoction was the dose level selected based on the hypoglycemic efficacy 
previously assayed with S. sonchifolius leaves [25].  
 
2.3. Phytochemical analysis of the aqueous extract 
2.3.1. Infrared (IR) spectroscopy 
 The analysis of the dry lyophilized residue from 10% decoction was performed by IR 
spectroscopy using a Perkin- Elmer 1600 FT-IR spectrophotometer.  
2.3.2. Thin-layer chromatography (TLC) analysis 
  
 TLC was developed to identify phenolic acids in decoction of S. macroscyphus by 
comparison with authentic samples using different solvents and detection systems as 
described previously [5]. Briefly, Merck aluminum sheets of Silica gel 60 F254 were used. 
For 3-caffeoylquinic acid (3-CQ) identification, plates were developed with n-butanol:acetic 
acid:water (10:1.75:8) or ethyl acetate:formic acid:glacial acetic acid:water (100:11:11:27). 
For caffeic acid (CAF) identification, plates were developed with n-hexane:ethyl 
acetate:acetic acid (4:6:0.15). Detection was performed by (i) fluorescence at 366nm 
(Mineral Light Lamp, Model UV GL, multiband UV 254/366, UVP San Gabriel, USA), (ii) 
spraying with a 1% solution of 2-aminoethyldiphenylborinate in methanol and then with a 5% 
solution of polyethylene glycol in ethanol and (iii) spraying with a 1% solution of FeCl3 in 
methanol. 
 
2.3.3. HPLC analysis 
 The HPLC analysis of the aqueous extract of S. macroscyphus leaves was performed 
using a Gilson 322 HPLC (binary pump) with a Gilson UV/VIS-152 Detector, Rheodyne 
injector with 20 µL loop and Unipoint software. In order to characterize the phenolic acids, a 
GraceSmart RP18 analytical column (5 µm; 4.6 mm x 250 mm) was employed using two 
different solvent programs, as previously described for characterize 3-CQ, CAF, 3,4-di 
caffeoylquinic (3,4-DCQ) acid, 3,5-dicaffeoylquinic (3,5-DCQ) acid and 4,5 dicaffeoylquinic 
(4,5-DCQ) acid of S. sonchifolius leaves [25]. 3-CQ and CAF were obtained from Sigma 
Chemical Company. Reference samples of all the three DCQ acids were obtained from Ilex 
paraguariensis [26].  
 In order to characterize the presence of the sesquiterpene lactone polymatin A in 
aqueous extract of leaves, a third solvent program was used. The binary mobile phase 
consisted of solvent A (0.5% acetic acid water solution) and solvent B (0.5% acetic acid 
acetonitrile solution). Elution was achieved with the following linear gradient: 0 to 45% B in 
  
30 min. Isocratic elution occurred with 45% B in 30 to 50 min, 45 to 100% B in 50 to 80 min. 
The flow rate was 1.3 mL min−1 . UV detection was carried out at 254 nm; 0.01 sensitivity. 
Injection volume: 20 µL. The presence of polymatin A in 10% decoctions was evaluated by 
comparison of retention times and UV spectra of purified polymatin A (see section 2.4). 
 
2.3.4 Analysis by Gas Chromatography coupled to a Mass Detector (GC-MS) 
 Dried 10% decoction (50 mg) was suspended in water (20 mL) and then extracted 
with chloroform (15 mL). The organic phase was recovered and the solvent was evaporated 
to afford a dry residue. GC-MS analysis were recorded using a Hewlett-Packard 5973 
selective mass detector coupled to a Hewlett-Packard 6890 Gas Chromatograph fitted with 
an Elite-5MS Perkin-Elmer column (5% phenylmethylsiloxane, 30 m x 0.25 mm i.d.; 0.25 µm 
film thickness); ionization energy 70 eV. Temperatures of injector, GC-MS interphase, ion 
source and selective mass detector were maintained at 220ºC, 280ºC, 230ºC and 150ºC, 
respectively; carrier gas was Helium with a flow rate of 1.1 mL min-1. The oven temperature 
was programmed as follows: 140-300°C at 2°C min-1 and then held at 300ºC for 5 min. The 
sample was injected (1.0 µL) as a 1% solution in methylene chloride. Polymatin A was 
characterized by: (a) comparison of their mass spectrum with a commercial GC-mass 
spectra library (National Institute of Standards and Technology, 1999, PC Version 1.7 of the 
NIST/EPA/NIH Mass Spectral Library. Perkin-Elmer Corp.: Norwalk, CT.)) and with mass 
spectrum reported in the literature [19,20]. 
 
2.4. Isolation and Purification of polymatin A 
 Whole air-dried leaves (406 g) of S. macroscyphus were soaked one by one in 
chloroform (2.95 L) placed in a glass tank. In this procedure each leaf was soaked in the 
solvent for 20 seconds at room temperature with a continuous and gentle swinging motion 
using a steel forceps. The extraction solvent was filtered through filter paper to eliminate 
  
small pieces of plant material and then was evaporated at reduced pressure to afford 7.06 g 
of residue which was dissolved with 120 mL of methanol at 40-45º C. Waxes were 
precipitated by adding dropwise water (50 mL) with magnetic stirring and the filtrate was 
evaporated to dryness to yield 5.33 g of a crude lactone mixture. The aim of this 
experimental procedure was to extract the contents of glandular trichomes of the leaf 
surface, which is rich in STLs. 
 To purify preparative amounts of polymatin A, a portion of crude lactone mixture (5.11 
g) was processed by chromatography on Silica gel Merck (230-400 mesh, 160 g) using 
hexane-ethyl acetate mixtures of increasing polarity (9:1; 4:1; 7:3; 3:2 and 1:1); 52 fractions 
were collected and grouped according to their TLC profiles and monitored by Infrared (IR) 
spectroscopy. The fractions showing strong γ-lactone absorption (1760-1780 cm-1) and 
containing fairly pure polymatin A (>92% by Gas chromatographic analysis) were reunited, 
the solvent evaporated and the gummy residue (3.32 g) was treated with ether (9 mL) and 
kept at 4°C for one week. This treatment induced crystallization of polymatin A. 
Recrystallization from heptane-ethyl acetate afforded 2.89 g of crystalline polymatin A, 
melting point 121-122°C (yield 0.71%, w/w of dry leaf weight). GC-MS analysis indicated a 
purity of 97.4% of polymatin A. NMR measurements were recorded on a Bruker 300 
AVANCE.  
 
2.5. Experimental animals 
 Adult male Wistar rats aged 8 to 12 weeks were selected for all the experiments. The 
animals were acclimated for 7 days, during which period each animal was examined to 
confirm suitability for the study. Suitability criteria were acceptable physical examination and 
body weight (b.w.), so that b.w. means for each group were comparable. At the beginning of 
the study, male rats weighed 200±20 g. They were obtained from the colony bred at the 
Department of Developmental Biology, INSIBIO (CONICET-UNT), Tucumán, Argentina. 
  
 The rats were housed in individual cages. The photoperiod (light on from 07:00 to 
19:00 h), air changes, room temperature (22±2ºC) and humidity (60-70% relative) were 
controlled. Animals were given free access to a powdered certified rodent diet obtained from 
a commercial source (Standard Food -Asociación de Cooperativas Argentinas - SENASA N° 
2706) and given tap water ad libitum. There were no known contaminants in food or water 
which were expected to interfere with the results of the study. 
 Throughout the experiments, all animals were maintained and handled according to 
international ethical guidelines for the care of laboratory animals (US Food and Drug 
Administration). The experimental protocol was approved by the Committee on Bioethics in 
Research of the National University of Tucumán and all experiments have complied with the 
current laws of Argentina (Ethical Framework of Reference for Biomedical Research in 
laboratory animals, Resol. D N° 1047 anexo II, 2005). 
 
2.6. Induction of experimental diabetes 
 Stable diabetes was induced by a single intraperitoneal injection to rats of freshly 
prepared streptozotocin (STZ, Sigma Chemical Company, St. Louis, MO, USA) solution in 
10mM sodium citrate buffer (pH 4.5), at a dose of 45 mg/kg body weight (b.w.). Control rats 
received only citrate buffer. Diabetes was achieved within 48 h in the majority of the animals, 
as determined by measuring of the fasting blood glucose levels and glucosuria. Only the 
animals with glycemia >350 mg/dL 2 days after STZ treatment were included in the study. 
 
2.7. Biochemical determinations 
 Blood glucose was measured with an Accu-chek® Active (Roche Diagnostics 
GnbHD-68298 Mannhein, Germany), based on glucose dye oxido-reductase mediator 
reaction. Urine glucose was determined by a reagent-based glucose oxidase-peroxidase 
enzymatic method (Bayer S.A. Diagnostic). Plasma insulin was determined by an Enzyme-
  
linked immunosorbent assay (rat/mouse Insulin ELISA kit, Linco Research, Inc.). Hemoglobin 
A1c (HbA1c) was separate by a chromatographic method using a cationic exchange resin 
(Hemoglobin A1c Kit, BioSystem S.A, Barcelona-Spain) and quantified by 
spectrophotometric reading at 415nm. 
 
2.8. Experimental design 
2.8.1. Dose optimization. Oral glucose tolerance test in normal healthy rats
 In order to choose the minimum effective hypoglycemic dose of the 10% decoction of 
S. macroscyphus leaves a range of variable doses (70, 140 and 280 mg dried extract/kg 
b.w.) was evaluated in normal healthy rats with the oral glucose tolerance test (OGTT), 
whereas the hypoglycemic action of polymatin A isolated from leaves was assessed with 
doses of 7, 14 and 28 mg dried powder/kg b.w.  
 OGTT was performed as described: the overnight fasted normal rats were divided into 
groups of six animals each. Basal (pre-treatment) blood glucose levels of all animals were 
recorded. Then, each group received orally, different doses of 10% decoction or polymatin A 
as mentioned above. The control group received vehicle (distilled water), whereas the 
standard drug glimepiride (5 mg/kg b.w.) was orally administered to rats in the positive 
control group. Thirty minutes later, the blood glucose level of each group was evaluated, and 
considered as 0 h value. Then, all the animals received orally a glucose solution (2 g/kg b.w.) 
and blood glucose was recorded at 15, 30, 45, 60 and 120 min after glucose loading.  
 
2.8.2. Assessment of hypoglycemic effect in normoglycemic rats 
2.8.2.1. Single-dose effect on fasting blood glucose.  
 Normal healthy male rats were fasted overnight (for 12 h) and pre-treatment fasting 
blood glucose levels were determined. The animals were divided into four groups of six rats 
each, and were given orally vehicle (distilled water, 1mL), 10% decoction (140 mg dried 
  
extract/kg b.w), polymatin A (14 mg/kg b.w.) or glimepiride (5 mg/kg b.w.). Blood samples 
were collected from the tail vein 1, 2 and 4 h after extract administration. 
2.8.2.2. Single-dose effect on post-prandial blood glucose.  
 Normal healthy male rats fasted overnight (for 12 h) were divided into four groups (n = 
6 rats) and were given orally vehicle (distilled water, 1mL), 10% decoction (140 mg dried 
extract/kg b.w), or polymatin A (14 mg/kg b.w.). Blood glucose levels were determined and 
referred to as 0 h value. Then, all the animals received sucrose (2g/kg b.w.) at 6:00 pm, and 
post-prandial blood glucose levels were monitored after 30, 60 and 120 min. 
 
2.8.3. Assessment of hypoglycemic activity in diabetic rats 
 STZ-diabetic rats were randomly divided into four groups (n=10 rats), and each group 
was treated with vehicle (distilled water, 1mL), 10% decoction (140 mg dried extract/kg b.w), 
polymatin A (14 mg/kg b.w.) or glimepiride (5 mg/kg b.w.), once a day for 4 weeks. All dry 
extracts were dissolved in distilled water (1mL)and administered at 6:00pm before eating 
using an intragastric tube. Fasting blood glucose level was determined in the blood sample 
from the tail vein every 7 days during the experimental period. Body weight, urine glucose 
level and plasma insulin levels were recorded weekly. Food intake was recorded daily.  
 
2.9. Acute toxicity studies 
 Acute oral toxicity of 10% decoction and pure polymatin A was studied by a single-
dose experiment. Healthy Wistar rats were randomly divided into groups of six animals. Each 
group included three males and three females with a weight of 200.0 ± 20.0 g that were 
orally given a single dose of 10% decoction or polymatin A. The doses tested were 3.5, 7.0 
and 14.0 g dry extract/kg b.w. for 10% decoction, representing 25, 50 and 100 times the 
effective hypoglycemic dose, and 0.7, 1.4 and 2.8 g dried powder/kg b.w. for pure crystalline 
polymatin A, representing 50, 100 and 200 times the effective hypoglycemic dose. The 
  
control group received only the vehicle (distilled water). Rats were observed continuously for 
1h after treatment to evaluate their behaviour (reduction in locomotion, aggressiveness, 
reaction to stimuli as tail pinch, noise, social interactions), neurologic (posture, exploratory 
movements, stereotypes, presence of clonic or tonic movements) and autonomic activity 
(piloerection, lacrimation, pupil size, respiratory pattern) and toxic effects. Then, the controls 
were carried out at 3.0 and 6.0 h post-dose on day 0 and twice daily (morning and afternoon) 
thereafter for 14 days. Food consumption, feces and urine (using reactive strips, Bayer S.A. 
Argentina) were also examined at the intervals specified above. 
 
2.10. Statistical analysis 
 The results from three independent experiments were presented as mean±SD. The 
significance of differences was evaluated using the paired Student’s t-test. When more than 
one group was compared with one control, significance was evaluated by one-way analysis 
of variance (ANOVA). When correspond, comparisons of blood glucose levels in different 
times and treatments were performed by two-way ANOVA followed by Bonferroni  post- hoc 
test. A p value <0.05 was considered statistically significant 
  
3. Results 
 
3.1. Phytochemical analysis of the aqueous extract (10% decoction) of S. 
macroscyphus leaves 
 In order to identify new active principles, we analyzed the constituents of a 10% 
decoction of S. macroscyphus leaves.  First, IR spectroscopy was performed. Absorption 
corresponding to γ-lactone carbonyl (1755–1780cm-1) was observed in the IR spectrum, 
indicating that SLTs are present in this extract. The IR spectrum (KBr) of the 10% decoction 
displayed strong absorptions at 3300cm-1 (phenol O-H stretch) and at 1600cm-1 (alkenyl C=C 
stretch), indicating that phenolic compounds are present in this extract. 
 TLC screening using authentic samples as reference and three different detection 
systems showed the presence of 3-CQ, CAF and caffeic acid derivatives, probably 
dicaffeoylquinic acids, in S. macroscyphus decoction. HPLC chromatograms of this extract 
using two different solvent programs (see Section 2.3.3) are shown in Fig. 2. Fig. 2A shows 
HPLC chromatogram using a Mobile phase I (detection at 326 nm) with peaks corresponding 
to 3-CQ and CAF. In Fig. 2B, the chromatogram using a Mobile phase II shows peaks of 3,4-
DCQ, 3,5-DCQ and 4,5-DCQ acids (detection UV at 326 nm). The chromatogram registered 
at 254 nm using a third solvent program shows that the 10% decoction of leaves has polar 
compounds and many peaks with low retention times (Fig.3A) It also shows a single peak 
with intermediate retention times (1) and therefore of intermediate polarity, likely an STL. The 
presence of polymatin A in 10% decoction was evaluated by comparison of this retention 
times with an authentic sample (Fig. 3B). The Fig. 3C shows an overlay of the spectra of 
polymatin A and decoction, indicating that peak (1) is likely polymatin A. A rapid and 
sensitive GC–MS method allowed the identification of the lactone as a minor component in 
the decoction (Fig.4) 
 
  
3.2. Chemical characterization of polymatin A isolated from S. macroscyphus leaves. 
 Crystalline polymatin A, was obtained as described in section 2.4. 1H NMR (300 MHz, 
CDCl3) δ in ppm (J in Hz; assignment): 6.85 dd (9.9 and 7.3 Hz; H-1), 6.33 dd (8.4 and 1.8; 
H-8), 6.24 d (3.2; H-13a); 6.11 qq (7.1 and 1.4; H-3’); 5.67 d (3.4; H-13b); 5.08 dd (10.5 and 
9.5; H-6); 4.94 broad d (10.5; H-5); 4.00 dd (10 and 8.4; H-9), 3.80 s (3H; -CO2Me); 2.82 d 
(10; -OH), 2.65 dddd (9.5, 3.4, 3.2 and 1.8; H-7), 2.48 m (H-2a), 2.33 m (H-3b), 2.24 m (H-
2b), 2.09 m (H-3a), 1.98 dq (3H; 7.3 and 1.4; H-4’), 1.88 broad s (6H; H-15 and H-5’). The 1H 
NMR spectra matched exactly with the data reported in the literature [19, 20]. The previously 
unreported 13C NMR data follow: 13C NMR (75 MHz, CDCl3): 169.21 (C-12), 167.42 (C-14), 
166.84 (C-1’), 144.19 (C-1), 139.46 (C-3’), 137.58 (C-4), 134.77 (C-11), 133.71 (C-10), 
126.89 (C-2’), 126.40 (C-5), 121.09 (C-13), 75.56 (C-6), 71.65 (C-8), 71.08 (C-9), 52.11 
(OMe), 51.42 ( C-7), 36.65 (C-3), 25.71 (C-2), 20.40 (C-5’), 16.81 (C-15), 15.75 (C-4’). MS 
(EI, 70 eV, GC-MS): m/z (%) M+ 390 (0.06), 359 (0.1), 307 (1), 290 (1), 272 (1), 258 (3), 240 
(2), 212 (3), 193 (2), 128 (3), 105 (4), 83 (100), 44 (43). 0.06] (38), 211 (43), 167 (8), 151 
(11), 149 (4), 125 (28), 109 (100), 108 (9), 83 (26), 82 (15), 81 (13), 79 (11), 67. HRMS: M+ 
390.1684 (calcd for C21H26O7 390.1678). 
 
3. 3. Dose optimization. Effect on OGTT of normal healthy rats 
 In a preliminary test we have demonstrated that the aqueous extracts of dried S. 
macroscyphus leaves exert a hypoglycemiant effect in rats [13]. In order to determine the 
minimum effective dose of both 10% decoction and polymatin A isolated from leaves of this 
plant, we have performed an OGTT.  
 As shown in Figure 5, a 10 % decoction of S. macroscyphus leaves has effective 
hypoglycemic activity. This effect was observed as early as 15 min after the glucose load, 
with all doses assayed (70, 140 and 280 mg/kg b.w.). Interestingly, 140 mg dry extract/kg 
b.w. was the only dose able to inhibit the hyperglycemic peak with an important reduction of 
  
blood glucose level at 30 min after glucose pulse, so it was selected for further experiments 
as the most effective dose. In addition, when the glycemic response was expressed as the 
increase of total area under the curve (IAUC), the values of IAUC of this treated group (S.m 
140 mg/kg b.w.) were significantly lower than the ones found in the others groups (Figure 5). 
Compared to control (H2O), the whole glycemic response was reduced by 62.25%, 75.40%, 
38.85% and 36.20% in animals treated with 70, 140 and 280 mg/kg b.w. of dry extract and 5 
mg/kg b.w. of glimepiride, respectively.  
 Figure 6 shows the result of OGTT for polymatin A at the doses assayed (7, 14 and 
28 mg/kg b.w.). From this test, we concluded that the lactone obtained from S. 
macroscyphus leaves has an important hypoglycemic effect, the minimum effective dose 
being 14 mg/kg b.w. This dose was able to inhibit the hyperglycemic peak at 15 min after 
glucose load and kept blood glucose levels stable up to 30 min. The glycemic response 
expressed as IAUC values showed a significant decrease in the group treated with a dose of 
14 mg/kg with respect to the control group (H2O), it being significantly lower than that in the 
other groups (Figure 6). Indeed, the whole glycemic response was reduced by 74.59% in 
animals treated with 14 mg/kg b.w. of crystalline lactone compared with control group; 
therefore, this dose was selected for the further experiments. 
 
3.4. Effect on blood glucose levels of normoglycemic rats 
3.4.1. Single-dose effect on fasting blood glucose 
 This experimental protocol was carried out with a single dose of 10% decoction of S. 
macroscyphus leaves (140 mg dry extract/kg b.w.) or polymatin A (14 mg /kg b.w.) to 
evaluate their effects on the fasting blood glucose of normoglycemic rats. The extract of 
leaves caused a moderate hypoglycemic effect 2 h after oral administration. As shown in 
Table 1, this effect was significant but not as strong as that of glimepiride. Conversely, 
  
treatment of fasting normoglycemic rats with polymatin A (14 mg/kg) had no significant 
glucose-lowering effect.  
 
3.4.2. Single-dose effect on post-prandial blood glucose 
 The ability of 10% decoction of S. macroscypus and polymatin A to inhibit 
postprandial hyperglycemia (anti-hyperglycemic effect) was evaluated using rats in the 
postprandial state, after sucrose overload. In rats treated with pure polymatin A (14 mg/kg), 
the blood glucose level reached a peak at 30 min after sucrose administration and returned 
to the initial level at 60 min (Table 2). This response was significantly different in control rats 
receiving H2O, in which blood glucose levels reached a peak at 30 min but failed to return to 
the initial level in the course of 120 min. Moreover, a single-dose of 10% decoction (140 
mg/kg) significantly prevented the hyperglycemic peak at 30 min after sucrose ingestion and 
was able to maintain blood glucose levels throughout the experiment (Table 2). Additionally, 
the treatment of normal rats with glimepiride, a positive control drug, produced a marked 
reduction in blood glucose that was maintained until the end of the experiment, as shown in 
table 2. 
 
3.5. Antidiabetic effect in STZ-diabetic rats 
 This study was carried out in order to evaluate the effect of a leaf extract (10% 
decoction) of S. macroscyphus and pure polymatin A on blood glucose levels in STZ-diabetic 
rats. This is the first report addressing the potential therapeutic effect of S. macroscyphus 
leaves on diabetes mellitus. The treatment for 4 weeks of diabetic animals with a 10% 
decoction at a dose of 140 mg/kg/day was able to produce a significant decrease in blood 
glucose levels compared with untreated diabetic animals (Figure 7). At the end of the 
experimental period, the blood glucose level was significantly lower with respect to the pre-
  
treatment values (p <0.05) and also compared to the glucose level of untreated diabetic 
group (p <0.001). At this time, glycemia was approximately 32% lower than before treatment.  
 When diabetic rats received polymatin A (14 mg/kg) daily for 4 weeks a significant 
reduction in fasting blood glucose was detected (Figure 7). At the end of the experimental 
period, the blood glucose levels was significantly lower with respect to the untreated diabetic 
group (p <0.001) and statistically different to pre-treatment values (p <0.05). Interestingly, at 
this point, the statistical analysis showed that polymatin A (14 mg/kg) was as effective as 
glimepiride and was more effective than S. macroscyphus decoction.  
 Body weight of treated and control animals after 28 days of treatment are shown in 
Table 3. There were no significant differences in the initial weight of treated animals 
compared to controls (data not shown, see section 2.5 Criteria of suitability). At the end of 
the experimental period (4 weeks), a marked decrease in body weight was observed in 
diabetic rats compared to normal healthy animals as a consequence of disease progression. 
Interestingly, daily administration of a 10% decoction or polymatin A resulted in a significant 
increase in body weight compared to untreated diabetic rats which was similar to the one 
caused by treatment with glimepiride (Table 3).  
 The diabetic animals treated with 10% decoction, polymatin A or glimepiride showed 
a decrease in daily standard rodent diet consumption compared with the untreated diabetic 
group but these intakes were significantly higher than those in the normal group (Table 3). 
 It was demonstrated that after a 4-week treatment of diabetic rats with a 10% 
decoction or polymatin A, urinary glucose excretion was significantly decreased compared 
with the untreated diabetic group, although these values were higher than in the normal 
group (Table 3). These results are in agreement with the improvement in blood glucose 
levels of treated diabetic rats. 
 As shown in Table 3, the relative concentration of Hb A1c in normal rats at the end of 
the experimental period was 6.03±1.82%. These levels increased in untreated STZ-diabetic 
  
animals as a result of poor glycemic control in the previous 4 weeks (equivalent to the 
lifetime of the erythrocytes). HbA1c levels declined significantly 4 weeks following the 
treatment with the 10% decoction or polymatin A, indicating that both treatments led to 
acceptable glycemic control in diabetic animals.  
 Figure 8 shows the effects of different treatments on blood glucose and plasma 
insulin levels of diabetic rats at the end of the experimental period (day 28). At this time, both 
the 10% decoction and polymatin A produced a significant decrease in blood glucose levels, 
although there was no significant increase in plasma insulin levels. In this experimental 
model, similar results were observed in rats treated with glimepiride, a reference 
hypoglycemiant drug (Fig. 8). However, all treatments significantly improved the fasting blood 
glucose/insulin ratio compared to the diabetic control group by 37.6% with the 10% decoction 
treatment, 61.9% with polymatin A treatment and 67.7% with glimepiride treatment.  
 
3.6. Acute toxicity studies 
 Acute oral toxicity of the 10% decoction and pure polymatin A was evaluated in 
normal healthy rats. The doses assayed were 25, 50 and 100 times greater than the effective 
hypoglycemic dose of the 10% decoction and 50, 100 and 200 times than the effective 
hypoglycaemic dose of polymatin A. No deaths or acute toxic effect (changes in behavior or 
posture, presence of convulsions or occurrence of secretions) were reported within 14 days. 
All treatments were well tolerated and did not produce adverse nutritional effect .No 
gastrointestinal symptom such as diarrhea or constipation were observed at the doses 
assayed. Volume, pH and urine specific gravity were within normal ranges. No nitrites, 
protein or blood were detected in the urine samples of the animal groups treated with 
different doses of the 10% decoction or polymatin A throughout 14 days of control. In this 
experiment no evidence of acute toxicity was found at any dose level up to the highest dose 
tested of the 10% decoction (14.0 g dry extract/kg b.w., 100 times the effective hypoglycemic 
  
dose) or of polymatin A (2.8 g dried powder /kg b.w., 200 times the effective hypoglycemic 
dose). These doses represent the no-observed-adverse-effect level (NOAEL), indicating that 
the safety margin of the extract and polymatin A is high. 
 
  
4. Discussion 
 In recent years, the prevention and control of complications associated with diabetes 
have become one of the key issues in medical research, and the search for new 
pharmacologically active agents obtained by screening natural sources such as plants has 
become particularly relevant [27,28]. 
 In view of the above aspects the aim of the present study was to investigate the 
glucose-lowering activity of the leaf extract of S. macroscyphus and of polymatin A, the most 
abundant sesquiterpene lactone in its aerial parts.  
 S. macroscyphus is a species closely related to S. sonchifolius and possibly with 
similar biological activities [1]. An intensive search of the existing literature demonstrated that 
this is the first comprehensive report that analyzes its hypoglycemic effect. Since there is no 
precedent for the use of this plant in traditional medicine or of its biological activities, we 
selected a 10% decoction of S. macroscyphus leaves to test its glucose-lowering effects. 
This concentration was chosen taking into account that in a previous work we demonstrated 
the safety and hypoglycemic efficacy of a 10% decoction of S. sonchifolius leaves, a species 
used in folk medicine and closely related to S. macroscyphus. [25]. 
 S. macroscyphus represents a slight departure from previously studied Smallanthus 
species that contains a relatively large proportion of a class of 8-OH-9 acylmelampolides but 
otherwise fits the overall chemical profile of the genus [22]. The phytochemical analysis of 
the 10% leaf decoction showed that its major constituents were phenolic compounds. CAF 
and 3-CQ were readily detected and three dicaffeoil quinic derivates (3,4-DCQ, 3,5-DCQ and 
4,5-DCQ ) were found also found to be constituents of the decoction. Moreover, a rapid and 
sensitive GC–MS method allowed the identification of polymatin A as a minor component in 
the decoction.  
  
 A number of studies have shown that the caffeic acid and chlorogenic acid present in 
several plants exhibited hypoglycemic activity and antioxidant properties in experimental 
animals [29,30,31,32]. The presence of these compounds together with dicaffeoil quinic 
derivates led us to think that they could be hypoglycemic principles of the decoction. Indeed, 
in the current study, we noticed for the first time an important hypoglycemic activity in the 
10% decoction of S. macroscyphus leaves in a dose-dependent manner, as shown by an 
OGTT in normal rats. While all doses tested were effective in the prevention of a 
hyperglycemic peak within 15 minutes of the glucose load, 140 mg dry extract/kg b.w. was 
the only dose able to significantly reduce the blood glucose level at 30 min and maintain 
basal levels until the end of the test. The glycemic response, expressed as IAUC, was 
significantly lower with this dose than with the others ones assayed, so this was selected as 
the more effective hypoglycemic dose.  
 OGTT is an easy and widely used procedure that was originally developed to classify 
carbohydrate tolerance [33], and in the present study it was used to determine the ability of 
plant extracts to maintain the homeostasis of blood glucose after a glucose load in normal 
rats and to select an effective dose. The efficacy of the 10% decoction at a dose of 140 mg 
dry extract/kg b.w. was compared to the standard anti-diabetic drug glimepiride (5 mg/kg 
b.w.). In view of our results, it is possible that the glucose-lowering effect of the decoction 
could be mediated by an improvement in the glycemic control mechanisms, including insulin 
secretion and/or extrapancreatic pathways, as was suggested for sulfonylurea drugs [34]. 
 Oral administration of a single-dose of the 10% decoction (140 mg/kg) to fasted 
normal rats caused a slight lowering in plasma glucose without any serious hypoglycemic 
effect during the 4 h of the test. On the other hand, this extract effectively inhibited the post-
prandial hyperglycemic peak at 30 min after sucrose ingestion and maintained near-normal 
blood glucose levels throughout the experiment. The latter finding suggest that this treatment 
would prevent carbohydrate absorption after food intake via an inhibition of the enteric 
  
enzymes including α-glucosidase and α-amylase present in the intestinal brush borders [35], 
with a consequent potential to control the post-prandial hyperglycemia. 
 In the present study, the oral administration of glimepiride (5 mg/kg b.w.) as a positive 
control produced a significant hypoglycemic effect in either fasting or post-prandial 
conditions. It is known that glimepiride, a third-generation sulfonylurea, stimulates insulin 
secretion, but also reduces blood glucose levels acting in the liver and other extra-pancreatic 
tissues improving the insulin action or by an insulin-like effect [36]. In keeping with our 
findings, it is possible that the 10% decoction or some of its constituents could act by a 
similar mechanism, contributing to the observed hypoglycemic effect without hypoglycemia 
risk. Indeed, it has been shown that some bioactive plant compounds with an aromatic 
hydroxyl group may potentiate insulin action which, together with their function as 
antioxidants, can exert a beneficial effect on the control of glucose in the diabetes [37]. 
 In order to identify new metabolites with hypoglycemic activity, we isolated crystalline 
polymatin A from  S. macroscyphus leaves. Interestingly, we determined by OGTT in normal 
rats that this sesquiterpene lactone was an active hypoglycemic compound, the minimum 
effective dose being 14 mg/kg b.w. This dose was effective in the prevention of the 
hyperglycemic peak within 15 minutes of the glucose load, with a quick return to basal blood 
glucose values. So, this was selected for further experiment.  
 In a previous study we found that enhydrin, the most abundant sesquiterpene lactone 
in yacon leaves, was also effective in reducing post-prandial glucose and useful in the 
treatment of diabetic animals [5]. Sesquiterpene lactones are secondary plant metabolites 
widely distributed within the Asteraceae family that in recent years have acquired therapeutic 
relevance as single components for the local treatment of inflammation and for cancer 
therapy [38]. The present work represents the first report that analyzes the hypoglycemic 
effect of polymatin A isolated from S. macrocyphus leaves. 
  
 Interestingly, polymatin A at a dose of 14 mg/kg b.w. had no significant glucose-
lowering effects in fasting normoglycemic rats. However, it effectively normalized blood 
glucose level at 60 min of sucrose ingestion and the glycemic response expressed as IAUC 
was significantly lower than in the untreated control group (data not shown). This finding 
suggests that polymatin A at the assayed dose would exert its pharmacological properties by 
stimulation of insulin release or by an insulin-like effect, without reaching the magnitude of 
the effect of glimepiride. It should be noted that polymatin A improved the glycemic control 
without risk of hypoglycemia, which is one of the most undesirable side effects of diabetes 
treatments.  
 Control of blood glucose levels is critical in the early treatment of diabetes mellitus to 
prevent complications of the disease [39]. Consequently, investigation of the glucose 
lowering effects of the 10% decoction of S. macroscyphus leaves and Polymatin A on STZ-
induced diabetic rats was a matter of interest Daily treatment with a 10% decoction or 
polymatin A significantly decreased the blood glucose levels and maintained the effect 
throughout the experimental period (4 week). This hypoglycemic effect was particularly 
relevant at the end of the experimental period, in which the blood glucose levels were close 
to normal. These findings lead us to believe that perhaps a longer treatment is required to 
achieve tight glycemic control. 
 The HbA1c concentration in blood measures chronic glycemia and is widely used to 
judge the adequacy of diabetes treatment and adjust therapy [40,41]. In keeping with our 
findings, treatments of diabetic animals for 4 weeks with a 10% decoction of S. 
macroscyphus leaves or polymatin A significantly decreased HbA1c levels, indicating an 
acceptable glycemic control in treated rats. 
 In pre-clinical studies, the anti-diabetic effect of certain plant extracts is generally 
dependent on the dose of the diabetogenic agent and therefore on the degree of β-cell 
destruction [42]. Under our experimental conditions, STZ induced rapid and incomplete β-cell 
  
destruction, evidenced by lower plasma insulin levels and hyperglucemia. While treatments 
of STZ-diabetic rats with a leaf decoction or with polymatin A significantly lowered fasting 
blood glucose, they produced no marked increase in plasma insulin level. Interestingly, both 
treatments significantly improved the fasting blood glucose/insulin ratio. Under our 
experimental conditions, this ratio indicates that the same level of insulinemia is able to 
appropriately compensate the fasting hyperglycemia in treated animals compared with 
diabetic controls and therefore, there is a possibility that decoction and polymatin A could act 
as insulin-mimetic agents and/or improved the insulin action at the cellular level. Further 
studies are in progress to determine the precise mechanism involved. 
 Decreased body weight, polyphagia and increased urine glucose excretion are well-
known manifestations of diabetic state. In our studies, treatment of STZ-diabetic rats with a 
10% decoction or polymatin A for 4 weeks caused both a significant gain in body weight and 
a decrease in daily food intake compared with untreated STZ-diabetic rats. Moreover, the 
treated animals reduced urinary glucose excretion. These results would be related to the 
high effectiveness of the extract and of polymatin A in decreasing the fasting blood glucose 
levels at 4 weeks of treatment. This is an additional advantage, confirming thereby the 
antidiabetic activity of the bioactive compounds. 
 In order to evaluate acute toxic effect in healthy adult rats, a wide range of doses of a 
10% decoction of S. macroscyphus leaves and polymatin A were assayed. The lack of toxic 
effects at all doses up to the highest dose tested, suggested that the lethal dose 50 (LD50) of 
the 10% decoction and of polymatin A would be above 14.0 and 2.8 g/kg b.w., respectively, 
which are significantly higher than the effective hypoglycaemic doses. These doses 
represent the no-observed-adverse-effect level (NOAEL), indicating that the safety margin of 
the extract and the polymatin A is high. 
Conclusion 
  
 The present study reveals that the 10% decoction of S. macroscyphus leaves and 
polymatin A, the main sesquiterpene lactone of the aerial part, have significant hypoglycemic 
and antidiabetic potential. This report represents a first step toward the assessment of a new 
medicinal plant and of new chemical entities isolated from it, which could help to manage 
diabetes more efficiently and safely.  
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Figure captions 
 
Figure 1. Chemical structure of polymatin A 
 
Figure 2. HPLC chromatogram of 10% decoction from S. macroscyphus leaves. Grace 
Smart RP18 analytical column (5 µm; 4.6 mm x 250 mm). A) Mobile phase I: solvent (a), 5% 
acetic acid water solution; solvent (b), methanol. Linear gradient: 20 to 33.5% (b) in 60 min. 
Flow rate: 0.7mL min−1. B) Mobile phase II: solvent (a), 2% acetic acid water solution; solvent 
(b), 2% acetic acid–methanol solution. Gradient: 15-40% (b) in 30 min; 40-75% (b) in 10 min 
and 75-85% (b) in 5 min. Flow rate of 0.7mL min−1. UV detection: 326 nm. CAF: caffeic acid, 
3-CQ: 3-caffeoylquinic acid (chlorogenic acid), DCQ: dicaffeoilquinic acid. 
 
Figure 3. HPLC chromatogram of 10% decoction from S. macroscyphus leaves. Grace 
Smart RP18 analytical column (5 µm; 4.6 mm x 250 mm). A) Chromatogram of 10% 
decoction: Mobile phase: solvent (a) 0.5% acetic acid water solution; solvent (b) 0.5% acetic 
acid acetonitrile solution. Gradient: 0-45% (b) in 30 min, isocratic elution with 45% (b) in 30-
45 min, 45-100% (b) in 50-80 min. Flow rate: 1.3 mL min-1. UV detection: 254 nm. B) 
Chromatogram of purified polymatin A obtained from S. macroscyphus leaves. Column and 
conditions were identical as A. C) Overlaying chromatograms A and B. 
 
Figure 4. GC-MS analysis of 10% decoction from S. macroscyphus leaves extracted with 
chloroform (see Material and Methods section). Polymatin A was characterized by 
comparison of its mass spectrum with commercial GC-mass spectra libraries and with those 
reported in the literature. 
 
  
Figure 5. Dose Optimization of 10% decoction of S. macroscyphus leaves (S.m.) through 
oral glucose tolerance test (OGTT). Normal rats administered S.m.: (-♦-) 70 mg/kg b.w.; (-■-) 
140 mg/kg b.w.; (--) 280 mg/kg b.w.; (……) normal rat administered glimepiride 5 mg/kg 
b.w.; (------) normal rats administered water, control group. Data are expressed as mean 
±SD. n= 6 rats / group. A) The blood glucose concentration was measured at the indicated 
times. B) Glycemic response is expressed as the increase of total area under curve (IAUC) 
in %. 
 * p<0.05 is considered to be statistically significant when compared with normal rats 
administered water. ** p<0.05 is considered to be statistically significant when compared with 
normal rat administered glimepiride. 
 
Figure 6. Dose Optimization of polymatin A (PA) through oral glucose tolerance test (OGTT). 
Normal rats administered PA: (--) 7 mg/kg b.w.; (-■-) 14 mg/kgb.w.; (--) 28 mg/kg b.w.; 
(……) normal rat administered glimepiride 5 mg/kg b.w.; (------) normal rats administered 
water, control group. Data are expressed as mean ±SD. n= 6 rats / group. A) The blood 
glucose concentration was measured at the indicated times. B) Glycemic response is 
expressed as the increase of total area under curve (IAUC) in %. 
 * The mean is considered to be statistically significant when compared with normal rats 
administered with water (p<0.05). ** The mean is considered to be statistically significant 
when compared with normal rat administered with glimepiride (p<0.05). 
 
Figure 7. Effect of a 4 weeks oral treatment with 10% decoction (S.m.) and polymatin A (PA) 
of S. macroscyphus leaves on blood glucose levels of diabetic rats. (--) S.m.140 mg/kg 
b.w/day.; (-■-) PA 14 mg/kg b.w./day; (--) glimepiride 5 mg/kg b.w./day; (……) water 
(diabetic control rats). Data are expressed as mean ±SD. Data was analyzed by two-way 
  
ANOVA followed by Bonferroni post-hoc test. The mean is considered to be statistically 
significant when compared to pre-treatment values of respective treatment group (#p<0.05). 
The mean is considered to be statistically significant when compared with blood glucose 
levels of diabetic control rats ( p<0.05, p<0.01, p<0.001). n=10 rats / group.  
 
Figure 8. Effect of an oral treatment with 10% decoction of S. macroscyphus leaves (S.m.) 
and polymatin A (PA) on A) fasting blood glucose levels and B) plasma insulin levels of 
diabetic rats at the end of the experimental period (day 28). Data are expressed as mean 
±SD. n=10 rats / group. * The mean is considered to be statistically significant when 
compared with diabetic control rats (p<0.05). ** The mean is considered to be statistically 
significant when compared with normal rats (p<0.05). 
 
 
 
  
Figure 1 
 
 
 
 
 
 
 
  R1: Ang; R2 : OH 
 
 
C. Serra-Barcellona et al. 
O
O
CO2Me
OR1
R2
2
3 5
6
7
8
9 101
13
15
12
11
  
Figure 2.  
 
 
 
 
C. Serra-Barcellona et al. 
 
  
Figure 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. Serra-Barcellona et al. 
Polymatin A 
 2
9.
81
 
1 
 2
9.
66
 
A 
B 
C 
  
 
 
 
C. Serra-Barcellona et al. 
 
Polymatin A 
Figure 4. 
  
Figure 5.  
 
 
 
C. Serra-Barcellona et al. 
A 
B 
  
Figure 6. 
 
 
C. Serra-Barcellona et al. 
  
Figure 7. 
 
 
 
 
C. Serra-Barcellona et al. 
# 
 
 
 
 
# 
# 
# 
# 
# 
#  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#  
 
 
 
 
 
  
Figure 8 
 
 
 
 
C. Serra-Barcellona et al. 
 
A 
B 
* 
 * 
** 
** 
** ** ** ** 
 * 
** 
  
 
 
Table 1. Effect of 10% decoction of S. macroscyphus leaves and polymatin A on fasting 
blood glucose level in normal rats. 
 
Animal Groups Glucose (mg/dl) Post-treatment 
 Pre-
treatment 
Glucose 
(mg/dl) 
 
1 h 
 
 
2 h 
 
 
4 h 
 
 
Normal +distilled 
water (control) 
 
 
90.1±3.3 
 
91.6±27 
 
89.8±3.2 
 
79.8±5.12 
 
Normal+10%decoction 
(140mg/kg) 
 
 
90.3±4.1 
 
86.3±2.7 
 
64.2±3.21,2 
 
78.3±4.12 
Normal+polymatin A 
(14 mg/kg) 
 
88.6±3,7 86.9±3.8 85.0±2.2 80.7±2.72 
Normal+glimepiride 
(5mg/kg) 
 
89.2±3.3 79.2±3.1 43.4±3.71,2 48.3±4.01,2 
 
Data are mean±SD. N=6 rats per group. 
1 Mean is considered to be statistically significant when compared with Normal+distilled water 
(control) group (p<0.05). 
2 Mean is considered to be statistically significant when compared with pre-treatment value 
(p<0.05). 
  
 
Table 2 . Effect of 10% decoction of S. macroscyphus leaves and polymatin A on post-
prandial blood glucose level in normal rats  
 
Animal Groups Post-prandial (sucrose overload)  
blood glucose level (mg/dl) 
 0 min 30 min 60 min 120 min 
 
Normal +distilled 
water (control) 
 
 
105.7±3.5 
 
140.3±2.5 
 
136.3±2.5 
 
147.7±2.5 
Normal+10%decoction 
(140mg/kg) 
 
113.2±4,5 126.0±4,01 131.8±4.0 125.4±13.01 
Normal+polymatin A 
(14 mg/kg) 
 
112.0±5.5 142.7±5.0 108.3±3.01 110.0±7.51 
Normal + glimepiride 
(5mg/kg) 
108.7±2.5 97.7±3.41 66.4±3.51 50.1±4.01 
 
Data are mean±SD. N=6 rats per group. 
1 Mean is considered to be statistically significant when compared with Normal+distilled water 
(control) group (p<0.05). 
  
Table 3. Effect of 10% decoction of S. macroscyphus leaves and polymatin A on body 
weight, food intake, urine glucose and HbA1c level in STZ-diabetic rats (after 28 days of 
treatment) 
 
Animal Groups Body weight 
(g) 
Food intake 
(g/kg 
b.w./day) 
Urine glucose 
(   ) 
Hb A1c (%) 
 
Normal (control) 
 
294.7±7.3 
 
56.1±0.1 
 
ND 
 
6.03±1.82 
     
Diabetic control 
 
166.20± 9.0 60.3±0.3 1,000±10 14.99±0.172 
Diabetic+10%decoction 
(140mg/kg/day) 
 
241.73±13.661 
 
59.7±0.21,2 750±101,2 9.73±2.521 
Diabetic+polymatin A 
(14 mg/kg/day) 
 
227.53±14.531 58.4±0.21,2 750±101,2 8.89±0.751,2 
Diabetic+glimepiride 
(5mg/kg/day) 
 
214.70±14.141 58.2±0.51,2 500±101,2 6.94±1.241 
 
Data are mean±SD. N=10 rats per group. 
1
 Mean is considered to be statistically significant when compared with Diabetic control group 
(p<0.05). 
2 Mean is considered to be statistically significant when compared with Normal (control) 
group (p<0.05). 
  
 
 
Highlights 
• This is the first report on Smallanthus macroscyphus as a new source of antidiabetic 
compounds. 
• A 10% decoction of S. macroscyphus leaves has a significant hypoglycemic effect. 
• Polymatin A, a sesquiterpene lactone of the leaf, has a significant hypoglycemic 
activity. 
• Acute toxicity studies in rat demonstrated that the use of decoction and polymatin A is 
safe. 
 
